Pulled Myeloma Drug Improves Survival in Trial

(MedPage Today) -- SAN DIEGO -- A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed or refractory multiple myeloma should smooth the way for the drug's reintroduction to...